The One Lambda Devyser Accept cfDNA Assay is a next-generation sequencing (NGS) solution for monitoring donor-derived cell-free DNA (dd-cfDNA) in solid organ transplant recipients.
Protocolised post-transplant monitoring has the potential to facilitate personalised immunosuppression and reduce premature graft loss through earlier intervention, with elevated dd-cfDNA an earlier marker of allograft dysfunction than e.g. creatinine and HLA DSA.
One Lambda Devyser Accept cfDNA
Unrivalled sensitivity (limit of detection 0.1%)
Simple, efficient workflow and next-day results
“We suggest that clinicians consider measuring serial plasma dd-cfDNA in patients with stable graft function to exclude the presence of subclinical antibody-mediated rejection.”
Resources
Get in touch with the VH Bio team to arrange a demonstration and have your questions answered.
"*" indicates required fields
Discover how Accept cfDNA is transforming patient care:
“The INDEL-based NGS assay [One Lambda Devyser Accept cfDNA] is a promising novel tool for detecting and monitoring dd-cfDNA in renal transplant recipients with an easy-to-implement workflow.”
